Home > Insider Trading > Filing (0001209191-18-052550)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1337553	Aerie Pharmaceuticals Inc	AERI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1252014	J Richard Rubino	C/O Aerie Pharmaceuticals, Inc. 4301 Emperor Blvd., Suite 400 Durham NC 27703	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2018-09-26	49,500	$60.18	334,236	No	4	S	Direct
Common Stock	Disposition	2018-09-26	500	$61.01	333,736	No	4	S	Direct
Common Stock	Disposition	2018-09-27	16,497	$60.36	317,239	No	4	S	Direct
Common Stock	Disposition	2018-09-27	108	$61.01	317,131	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Following the sales reported on this Form 4, the reporting person's Rule 10b5-1 plan dated August 24, 2018 is completed.
The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $60.00 to $60.95, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.00 to $61.05, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $60.00 to $60.90, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.00 to $61.15, inclusive.